Skip to Content
NCI Formulary
Contact NExT
Show menu
Search this site
Last Updated: 06/30/17

Information below provided by the Pharmaceutical Company.

AZD1775 (MK-1775)

Agent Description

AZD1775 is a potent, selective inhibitor of WEE1 that deregulates CDK1 and CDK2 activity leading to abrogation of the replication stress response and the G2/M checkpoint.

Mechanism of Action

WEE1 kinase inhibition

Classification

Small molecule WEE1 kinase inhibitor

Molecular Targets

WEE1

Monograph

AZD1775 is under investigation as a monotherapy in cancers with high replication stress and in combination with chemotherapy and the PARP inhibitor olaparib.

Studies of Interest

Areas of interest:

  • Monotherapy other than in ovarian, TNBC, SCLC, endometrial, prostate, renal, AML, sarcoma and CRC
  • Combinations with olaparib other than in ovarian, endometrial, pancreas
  • Combination with other DNA damage response (DDR) agents (e.g., ATR inhibitors, ATM inhibitors, other novel checkpoint kinase inhibitors)
  • Combination with Immunotherapy
  • Combination with Chemotherapy, including novel chemotherapy and formulations
  • Combination with radiation
  • Novel/Novel agent combinations (e.g., VEGF, mTOR, AKT)
  • Other study designs:
    • Neo-adjuvant therapy
    • Window studies
    • Maintenance therapy
    • Agent administration sequencing studies
    • Basket-type approaches with DDR agents
    • Specific molecular segmented patient populations

Areas NOT of interest:

  • Monotherapy in ovarian, TNBC, SCLC, endometrial, prostate, renal, AML, sarcoma and CRC
  • Combinations with olaparib in ovarian, endometrial, pancreas
  • Combinations with carboplatin, gemcitabine or PLD
  • Studies in AML
  • Combination with Radiation or Cisplatin in GBM
  • Combinations in HNSCC
  • Combinations with Durvalumab/Tremelimumab
  • Pediatrics

Information collaborator would like included in investigator proposals

Clear line of site of how the study would lead to a registration intent study in the proposed setting

NOTE: Drug supply availability will be a limiting factor in the short term